NGSX Turnaround in full play!
30.01.12 20:36
#1
thekey
NGSX Turnaround in full play!
Ticker: NGSX
Preis: $1.04
Website: http://www.neurogesx.com
Shares Out (Mil) 29.69
Float (Mil) 11.40
Großer Insiderkauf für $2.8M bei $1.65
Finviz:http://finviz.com/quote.ashx?t=ngsx
keydata: http://www.dailyfinance.com/quote/nasdaq/...x-inc/ngsx/key-statistics
Insider: http://www.insidercow.com/history/....jsp?company=NGSX&B1=Search!





Preis: $1.04
Website: http://www.neurogesx.com
Shares Out (Mil) 29.69
Float (Mil) 11.40
Großer Insiderkauf für $2.8M bei $1.65
Finviz:http://finviz.com/quote.ashx?t=ngsx
keydata: http://www.dailyfinance.com/quote/nasdaq/...x-inc/ngsx/key-statistics
Insider: http://www.insidercow.com/history/....jsp?company=NGSX&B1=Search!
31 Postings ausgeblendet.
10.02.12 07:40
#36
Joschi307
Mit einem kräftigen Abschlag
NeurogesX (Nasdaq: NGSX) today announced that the Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) to the U.S. FDA did not recommend FDA approval of a new indication for Qutenza® (Capsaicin) 8% patch for the management of neuropathic pain (nerve pain) related to HIV associated peripheral neuropathy (HIV-PN).
While the FDA will consider recommendations of the Committee, the decision regarding the approval of a new indication is determined by the FDA. Currently, the Company's supplemental new drug application (sNDA) remains under evaluation, with Priority Review status granted by the FDA. A decision from the Agency is expected by March 7, 2012, under the Prescription Drug User Fee Act (PDUFA).
The Committee's recommendation followed today's presentations by the Company and the FDA. The Committee reviewed the efficacy and safety data from clinical studies of Qutenza® in the management of pain associated with HIV-PN.
Quelle: http://www.streetinsider.com/Corporate+News/...f+Qutenza/7157384.html
While the FDA will consider recommendations of the Committee, the decision regarding the approval of a new indication is determined by the FDA. Currently, the Company's supplemental new drug application (sNDA) remains under evaluation, with Priority Review status granted by the FDA. A decision from the Agency is expected by March 7, 2012, under the Prescription Drug User Fee Act (PDUFA).
The Committee's recommendation followed today's presentations by the Company and the FDA. The Committee reviewed the efficacy and safety data from clinical studies of Qutenza® in the management of pain associated with HIV-PN.
Quelle: http://www.streetinsider.com/Corporate+News/...f+Qutenza/7157384.html
17.02.12 13:53
#47
Joschi307
überverkauft und hoch überschuldet...
http://www.mysmartrend.com/news-briefs/mannkind/...y-ngsx-incy-mnkd-0
Da die FDA in 99% der Fälle der Empfehlung des Panels folgt, wird hier wohl bald ein Chapter 11 geben.
Da die FDA in 99% der Fälle der Empfehlung des Panels folgt, wird hier wohl bald ein Chapter 11 geben.
14.03.12 18:09
#51
thekey
price target $2.00
NGSX $0.61 analyst price target $2.00 - lets go!
http://www.theflyonthewall.com/permalinks/...-from-Neutral-at-Wedbush
http://www.theflyonthewall.com/permalinks/...-from-Neutral-at-Wedbush
29.06.12 00:17
#55
Joschi307
Neurogesx 0,28 $ (-22%)
http://...iew.com/news/jpo-issues-patent-to-neurogesx-ngx-1998-190612
29.06.12 17:21
#56
Joschi307
Neurogesx fliegt von der Nasdaq
http://www.benzinga.com/news/12/06/2708271/...ve-from-nasdaq-to-otcbb
18.04.13 17:41
#57
Joschi307
Neurogesx
sieht so aus,als deute sich ein Ende an
http://www.bizjournals.com/sanfrancisco/blog/...tenza-pain-patch.html
http://www.bizjournals.com/sanfrancisco/blog/...tenza-pain-patch.html
